Salt Lake City,
The purpose of this project is to find genes whose mutations cause Polycythemia Vera,
Essential Thrombocythemia and Primary Myelofibrosis.
Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), also
known as the Philadelphia Chromosome negative myeloproliferative disorders (MPDs), are not
congenital, but acquired. The purpose of this project is to find genes whose mutations cause
these disorders, as well as improve diagnostic measures for these diseases. When this is
accomplished new therapies to control and eventually cure the disease can be designed.
All subjects will be asked to donate 4-6 teaspoons of blood. On occasion, if the blood cells
from a particular sample do not grow well and the DNA from that sample is used up or other
tests are needed, we may ask to collect additional samples. In patients who have undergone a
bone marrow biopsy as part of their clinical evaluation, we will test the reproducibility
between pathologists for the revised 2008 WHO diagnostic criteria to diagnose
myeloproliferative disorders (MPD).
1. Patients with an elevated hemoglobin concentration (>18 in males and >16 in females)
and who are suspected to have congenital or acquired primary polycythemia
2. Patients with a persistent thrombocytosis (>400,000) that does not have an obvious
3. Patients with a bone marrow biopsy that shows increased cellularity and fibrosis
4. Patients where there is clinical concern for primary myelofibrosis, such as anemia in
combination with leukocytosis, thrombocytosis, splenomegaly and/or a
leukoerythroblastic blood smear
5. Patients with thrombosis at unusual sites, such as Budd-Chiari syndrome, can have
early PV before hemoglobin is elevated, these patients will also be included.
1. Subjects who have a known acquired cause of polycythemia (increased
hemoglobin/hematocrit) such as people living in high altitudes (in excess of 14,000
feet), subjects with heart disease, left to right heart shunt, severe hypoxia or
severe pulmonary disease will be excluded from this study.
2. Subjects with a known acquired cause of thrombocytosis.
3. Subjects will be excluded if they cannot demonstrate decision making capacity
sufficient to agree or decline the blood drawing or use of their blood for the study.